Abstract
Sodium ozagrel inhibits platelet aggregation through thromboxane (TX) synthetase inhibition. In vitro, the combination of antiplatelet agents with plasminogen activators (PAs) is more effective for thrombolytic therapy than are PAs alone. Therefore, the influence of sodium ozagrel on platelet rich plasma (PRP) clot lysis was investigated in this study. Firstly, PRP clot lysis was performed: PRP clots containing sodium ozagrel were lyzed by a urokinase-type PA. PRP clot lysis was significantly enhanced by sodium ozagrel in a dose-dependent manner. Secondly, clot solubility was investigated by a urea solubility test. The solubility of PRP clots was enhanced by sodium ozagrel in a dose-dependent manner. Moreover, the influence of sodium ozagrel on the density of PRP clots was studied. The density of the PRP clots was decreased by sodium ozagrel in a dose-dependent manner. PAI-1 antigen which was released from activated platelets was reduced by sodium ozagrel in a dose-dependent manner. These findings indicate that the enhancement of PRP clot lysis by sodium ozagrel is due to enhanced solubility, decreased density and reduced PAI-1 antigen release.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
